The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Clobazam Thame 5mg/5ml Oral Suspension



Syri Pharma Limited t/a Thame LaboratoriesPA22697/006/001

Main Information

Trade NameClobazam Thame 5mg/5ml Oral Suspension
Active SubstancesClobazam
Dosage FormOral suspension
Licence HolderSyri Pharma Limited t/a Thame Laboratories
Licence NumberPA22697/006/001

Group Information

ATC CodeN05BA Benzodiazepine derivatives
N05BA09 clobazam

Status

License statusAuthorised
Licence Issued19/02/2016
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in schedule 4, part 1 to the Misuse of Drugs Regulations 2017.
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportPDF Version
« Back